Nutriband Inc. (NASDAQ: NTRB) and Its Innovative Abuse-Deterrent Drug Delivery Platform: A Comprehensive FAQ

What is Nutriband Inc. known for?

Nutriband Inc. is primarily engaged in the development of transdermal pharmaceutical products, focusing on abuse-deterrent drug delivery systems like its AVERSA Fentanyl and Buprenorphine patches.

Why is Nutriband’s AVERSA technology significant?

AVERSA technology is significant because it can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential, addressing a critical public health issue.

What are the projected sales for Nutriband’s AVERSA Fentanyl and Buprenorphine?

AVERSA Fentanyl is projected to reach peak annual U.S. sales of $80 to $200 million, while AVERSA Buprenorphine is projected to achieve peak U.S. sales between $70 and $130 million upon approval.

How does Nutriband’s technology work?

Nutriband combines transdermal innovation with abuse-deterrent science to create patches that deter abuse and misuse while reducing the risk of accidental exposure, leveraging a scalable platform for global patent protection.

Where can I find more information about Nutriband Inc.?

More information about Nutriband Inc. can be found on their website at www.Nutriband.com or in the company’s newsroom at https://ibn.fm/NTRB.

What makes AVERSA Fentanyl unique?

AVERSA Fentanyl is poised to be the world’s first opioid patch designed to deter abuse and misuse and reduce the risk of accidental exposure of transdermal fentanyl patches, marking a significant advancement in drug delivery technology.

Who is behind the development of Nutriband’s products?

Nutriband Inc. is the company behind the development of these innovative abuse-deterrent transdermal products, combining scientific innovation with a scalable platform for global impact.

When are Nutriband’s products expected to be available?

The content does not specify exact availability dates, but Nutriband’s products are advancing through development, with AVERSA Fentanyl and Buprenorphine candidates on track for global patent protection.

What are the benefits of Nutriband’s scalable platform?

The scalable platform allows for the efficient development and global patent protection of abuse-deterrent transdermal products, enabling Nutriband to address a wide range of public health needs with innovative solutions.